Advances in neuromodulation are challenging conventional approaches and expanding non‑drug treatment options for ...
JERUSALEM, Dec. 02, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced final positive results from its pivotal multicenter trial assessing the safety and ...
This is the Company’s third FDA-cleared indication for its Deep TMS System, and is the first FDA clearance in the addiction space for any TMS device Dr. von Jako added, “Importantly, this is the first ...
The outpatient procedure provides noninvasive magnetic stimulation to areas of the brain known to be associated with addiction. The Food and Drug Administration (FDA) has cleared BrainsWay’s Deep ...
With this update, eight major payers and the US Department of Veterans Affairs now either cover or include policy language supporting accelerated TMS treatment approaches, representing over 57 million ...
The US Food and Drug Administration (FDA) has granted marketing approval for the BrainsWay deep transcranial magnetic stimulation (TMS) system to help adult smokers kick tobacco. This is the company's ...
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Nearly a decade after reeling in the first FDA nod allowing its deep brain stimulation technology to help treat major depressive disorder, BrainsWay has doubled back with another agency-cleared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results